Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
cancer characterized by unbridled proliferation of malignant marrow stem cells with …
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
NG Daver, A Maiti, TM Kadia, P Vyas, R Majeti, AH Wei… - Cancer discovery, 2022 - AACR
TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …
distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML …
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
Abstract Treatment with Menin inhibitor (MI) disrupts the interaction between Menin and
MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of …
MLL1 or MLL1-fusion protein (FP), inhibits HOXA9/MEIS1, induces differentiation and loss of …
[HTML][HTML] Venetoclax resistance: mechanistic insights and future strategies
F Ong, K Kim, MY Konopleva - Cancer Drug Resistance, 2022 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is historically associated with poor prognosis, especially in
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …
older AML patients unfit for intensive chemotherapy. The development of Venetoclax, a …
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study
G Garcia-Manero, AD Goldberg, ES Winer… - The Lancet …, 2023 - thelancet.com
Background TP53-mutated acute myeloid leukaemia is associated with poor outcomes.
Eprenetapopt (APR-246) is a first-in-class, small-molecule p53 reactivator. We aimed to …
Eprenetapopt (APR-246) is a first-in-class, small-molecule p53 reactivator. We aimed to …
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors
Y Xu, H Ye - Experimental Hematology & Oncology, 2022 - Springer
Venetoclax is a new type of BH3 mimetic compound that can target the binding site in the
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
BCL-2 protein and induce apoptosis in cancer cells by stimulating the mitochondrial …
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
Background Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating
enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic …
enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic …
Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib …
NG Daver, P Vyas, S Kambhampati… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE Magrolimab is a first-in-class humanized monoclonal antibody against cluster of
differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis …
differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis …
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia
B Falini, MP Martelli - American Journal of Hematology, 2023 - Wiley Online Library
Several editions of the World Health Organization (WHO) classifications of lympho‐
hemopoietic neoplasms in 2001, 2008, and 2016 served as the international standard for …
hemopoietic neoplasms in 2001, 2008, and 2016 served as the international standard for …
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
A Bataller, A Bazinet, CD DiNardo, A Maiti… - Blood …, 2024 - ashpublications.org
Hypomethylating agents (HMAs) and venetoclax (Ven) represent the standard of care for
patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy …
patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy …